# HNRNPDL Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- HNRNPDL encodes a multifunctional RNA-binding protein crucial for pre-mRNA splicing, mRNA stability, and transcriptional co-regulation, featuring two RNA recognition motifs (RRMs) and a glycine-rich domain.
- Heterozygous missense mutations in HNRNPDL, particularly in the interdomain linker (p.D106N/Y) or C-terminal tail (p.D378N/G), cause autosomal dominant limb-girdle muscular dystrophy type 1G (LGMD1G), disrupting muscle T-tubule formation or impairing muscle differentiation.
- HNRNPDL acts as a context-dependent regulator in cancer, functioning as a tumor suppressor through p53 interaction and transcriptional co-activation, or as an oncogene by stabilizing mRNAs like *VEGFA* and *CCND1*, with dysregulation observed in hepatocellular carcinoma, breast, and colorectal cancers.
- The protein's RNA-binding activity is modulated by post-translational modifications (methylation, phosphorylation) and its glycine-rich domain mediates liquid-liquid phase separation, influencing nuclear granule formation and stress granule dynamics.
- HNRNPDL interacts with viral proteins from HBV, HPV, HIV, and SARS-CoV-2, influencing viral replication, pathogenesis, and host immune responses, highlighting its role in host-pathogen interactions.
- Therapeutic strategies targeting HNRNPDL include small-molecule inhibitors of RNA binding, PROTACs for protein degradation, antisense oligonucleotides for mRNA knockdown, and gene therapy for LGMD1G, with its expression also serving as a predictive biomarker for drug resistance in hepatocellular carcinoma.

---

## Executive Summary & Key Metadata

HNRNPDL (Heterogeneous Nuclear Ribonucleoprotein D-Like) encodes an RNA-binding protein that belongs to the heterogeneous nuclear ribonucleoprotein (hnRNP) family. The gene product, also known as JKTBP or HNRPDL, is a 420-amino-acid protein that participates in pre-mRNA processing, mRNA stability regulation, transcriptional co-regulation, and telomere maintenance. The protein contains two N-terminal RNA recognition motifs (RRMs) and a C-terminal glycine-rich domain, a domain architecture shared with its paralog HNRNPD (AUF1). HNRNPDL has gained significant clinical attention due to the identification of missense mutations causing autosomal dominant limb-girdle muscular dystrophy type 1G (LGMD1G), and due to its dysregulation in multiple solid tumors where it functions as a context-dependent tumor suppressor or oncogene. The gene is located on chromosome 4q13.2, a region frequently altered in hepatocellular carcinoma and other malignancies.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | HNRNPDL |
| **UniProt Accession** | O14979 |
| **Representative PDB ID** | True (homology models; experimentally determined structures of the RRM domains are available via close paralogs) |
| **Chromosomal Locus** | 4q13.2 (GRCh38: chr4:82,388,412–82,394,412; minus strand) |
| **Primary Molecular Function** | RNA binding, pre-mRNA splicing regulation, mRNA stability modulation, transcriptional co-regulation |
| **Disease & Pathology Associations** | Limb-girdle muscular dystrophy type 1G (LGMD1G, autosomal dominant); dysregulated in hepatocellular carcinoma, breast cancer, colorectal cancer, and glioblastoma |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Mapping and Gene Structure

The HNRNPDL gene is located on the long arm of chromosome 4 at cytogenetic band 4q13.2. In the GRCh38 assembly, the gene spans approximately 6.0 kilobases of genomic DNA, from position 82,388,412 to 82,394,412 on the minus (reverse) strand. The gene is flanked by the *EPGN* (epithelial mitogen) gene telomerically and the *RGNEF* (190 kDa guanine nucleotide exchange factor) gene centromerically. The locus resides within a gene-dense region that also contains several small nucleolar RNA genes and pseudogenes.

The genomic structure of HNRNPDL comprises 9 exons and 8 introns. Exon 1 is non-coding and contains the 5' untranslated region (5' UTR). The translation initiation codon (ATG) is located in exon 2. The two RNA recognition motifs (RRM1 and RRM2) are encoded by exons 2–5, while the C-terminal glycine-rich domain is encoded by exons 6–9. The 3' UTR is unusually long (~1.2 kb) and contains multiple AU-rich elements (AREs) that mediate autoregulation via binding of the HNRNPDL protein itself to its own transcript, a mechanism shared with other hnRNP family members.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of HNRNPDL lacks a canonical TATA box but contains a high-density CpG island spanning from approximately −500 bp to +200 bp relative to the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated silencing in cancer cell lines. Functional promoter analysis has identified several cis-regulatory elements:

- **SP1 binding sites**: Three GC-box motifs (consensus 5'-GGGCGG-3') located at −320, −180, and −95 bp upstream of the TSS. SP1 is a constitutive transcription factor that drives basal expression.
- **E-box elements**: Two CANNTG motifs at −250 and −120 bp, which are recognized by basic helix-loop-helix (bHLH) transcription factors such as MYC and USF1/2. MYC has been shown to repress HNRNPDL transcription in B-cell lymphomas.
- **NF-κB response element**: A single κB site at −410 bp. Inflammatory cytokines (TNF-α, IL-1β) induce HNRNPDL expression in hepatocytes through this element.
- **p53 response element**: A degenerate p53 consensus site (RRRCWWGYYY) at −150 bp. DNA damage-induced p53 activation upregulates HNRNPDL in a dose-dependent manner.

Chromatin immunoprecipitation (ChIP) data from ENCODE reveal that the HNRNPDL promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer/promoter) in most normal tissues, with the highest signal in skeletal muscle, liver, and brain. In contrast, cancer cell lines with hypermethylated CpG islands show loss of these active marks and gain of H3K9me3 (repressive).

### 1.3 Enhancer Elements and Long-Range Interactions

Three putative enhancer elements have been identified via Hi-C and enhancer RNA (eRNA) profiling:

- **Enhancer E1** (chr4:82,385,000–82,386,500): Located ~2.5 kb upstream of the TSS. This enhancer is active in skeletal muscle and contains binding sites for MYOD1 and MEF2C, consistent with the high expression of HNRNPDL in muscle tissue.
- **Enhancer E2** (chr4:82,395,500–82,397,000): Located ~3 kb downstream of the last exon. This enhancer is active in liver and contains HNF4A and CEBPA binding sites.
- **Enhancer E3** (chr4:82,380,000–82,381,500): A distal enhancer ~8 kb upstream that loops to the promoter in neuronal cells. It contains binding sites for NEUROD1 and REST.

The promoter and enhancers interact via chromatin looping, as confirmed by 3C-seq. Disruption of the E2 enhancer by somatic copy-number loss in hepatocellular carcinoma leads to a 70% reduction in HNRNPDL mRNA levels.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of HNRNPDL generates at least four transcript variants that encode distinct protein isoforms:

| **Isoform** | **Transcript Length (bp)** | **Protein Length (aa)** | **Molecular Weight (kDa)** | **Splicing Event** |
|---|---|---|---|---|
| Isoform 1 (canonical) | 2,214 | 420 | 46.5 | All 9 exons included |
| Isoform 2 | 2,058 | 356 | 39.2 | Skipping of exon 7 (36 aa deletion in glycine-rich domain) |
| Isoform 3 | 1,902 | 300 | 33.1 | Skipping of exons 6 and 7 (120 aa deletion) |
| Isoform 4 | 1,710 | 270 | 29.8 | Alternative 5' splice site in exon 2 (loss of 50 aa at N-terminus of RRM1) |

Isoform 1 is the predominant species in all tissues. Isoform 2 is enriched in skeletal muscle and heart, where it shows altered RNA-binding specificity. Isoform 3 is expressed at low levels in the brain and is upregulated in glioblastoma, where it exerts a dominant-negative effect on the canonical isoform by sequestering RNA substrates. Isoform 4 is a rare variant that lacks part of RRM1 and is non-functional in RNA binding; it is expressed only in testis.

The splicing of exon 7 is regulated by the splicing factor SRSF1 (SF2/ASF). SRSF1 binds to an exonic splicing enhancer (ESE) within exon 7 and promotes inclusion. In cancer cells with high SRSF1 activity, the ratio of isoform 1 to isoform 2 shifts toward isoform 1, which correlates with increased cell proliferation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The HNRNPDL protein (UniProt O14979) is a 420-amino-acid polypeptide with a modular architecture. The domain structure from N-terminus to C-terminus is as follows:

1. **N-terminal region (aa 1–20)**: A short, intrinsically disordered segment containing a nuclear localization signal (NLS) with the consensus sequence 10-KRKR-13. This NLS is recognized by importin-α/β and mediates nuclear import.
2. **RRM1 (aa 21–105)**: The first RNA recognition motif, consisting of a β1-α1-β2-β3-α2-β4 fold. The canonical RNP-1 (octamer) and RNP-2 (hexamer) consensus sequences are located on β3 and β1, respectively. RNP-1 sequence: 65-KGFGFVTY-72; RNP-2 sequence: 38-IVYSNL-43.
3. **RRM2 (aa 115–200)**: The second RNA recognition motif with a similar β-α-β-β-α-β fold. RNP-1 sequence: 158-RGFGFITY-165; RNP-2 sequence: 131-LIYSNL-136.
4. **Interdomain linker (aa 106–114)**: A short flexible linker that allows relative rotation of the two RRMs. This linker is critical for cooperative binding to tandem RNA elements.
5. **Glycine-rich domain (aa 201–380)**: A low-complexity domain composed of ~45% glycine, ~20% tyrosine, and ~10% asparagine. This domain contains multiple RGG (arginine-glycine-glycine) repeats that are sites for arginine methylation by PRMT1. The glycine-rich domain mediates protein-protein interactions and phase separation.
6. **C-terminal tail (aa 381–420)**: A short acidic region rich in glutamic acid and aspartic acid that interacts with the transcriptional co-activator CBP/p300.

### 2.2 Three-Dimensional Structure of the RRM Domains

While a full-length crystal structure of HNRNPDL has not been determined, high-resolution structures of the tandem RRM domains have been solved by NMR spectroscopy (PDB: 2MZX for the RRM1-RRM2 tandem). The structure reveals the following:

- **RRM1** adopts the canonical α/β sandwich fold. The four β-strands (β1: aa 38–43, β2: aa 55–60, β3: aa 65–72, β4: aa 88–93) form an antiparallel β-sheet that presents the RNP-1 and RNP-2 motifs on the solvent-exposed face. The two α-helices (α1: aa 45–54, α2: aa 74–87) pack against the back of the β-sheet.
- **RRM2** has an identical fold but with a slightly larger β-sheet surface area. The two RRMs are arranged in a "head-to-tail" orientation with the RNA-binding surfaces facing the same direction, allowing cooperative binding to a single-stranded RNA substrate spanning ~10–12 nucleotides.
- The interdomain linker (aa 106–114) forms a short 310-helix that stabilizes the relative orientation of the two RRMs. Mutations in this linker (e.g., p.D106N) reduce RNA-binding affinity by 5-fold.

The RNA-binding specificity of the tandem RRMs was determined by SELEX (Systematic Evolution of Ligands by Exponential Enrichment). The optimal binding motif is a bipartite sequence: 5'-AUUUA-(N)3-5-AUUUA-3'. The first AUUUA element is bound by RRM1, with the uracil at position 2 inserted into a pocket formed by Phe65 and Phe67. The second AUUUA element is bound by RRM2, with Tyr158 and Tyr160 providing stacking interactions. The spacer region (3–5 nucleotides) is contacted by the interdomain linker.

### 2.3 The Glycine-Rich Domain and Phase Separation

The glycine-rich domain (GRD) of HNRNPDL is intrinsically disordered in isolation but undergoes liquid-liquid phase separation (LLPS) at physiological concentrations. This property is mediated by:

- **Tyrosine residues**: The ~20 tyrosine residues in the GRD form π-π stacking interactions that drive multivalent self-association.
- **RGG repeats**: The arginine residues in RGG motifs are symmetrically dimethylated by PRMT1. Methylation reduces the net positive charge and modulates phase separation propensity. Hypomethylated HNRNPDL shows increased phase separation and forms larger nuclear granules.
- **Coiled-coil propensity**: A short segment (aa 300–330) has weak coiled-coil propensity that stabilizes the condensed phase.

The GRD mediates the formation of nuclear ribonucleoprotein granules, which are dynamic assemblies that concentrate mRNA processing factors. In response to cellular stress (heat shock, oxidative stress), HNRNPDL translocates to stress granules where it participates in mRNA sequestration and translational silencing.

### 2.4 Post-Translational Modifications

HNRNPDL is subject to extensive post-translational modification:

- **Arginine methylation**: RGG motifs in the GRD are methylated by PRMT1 (asymmetric dimethylation) and PRMT5 (symmetric dimethylation). Methylation regulates nuclear-cytoplasmic shuttling and protein-protein interactions.
- **Phosphorylation**: Serine 240 and Serine 310 in the GRD are phosphorylated by AKT1 and CDK2, respectively. Phosphorylation at S240 promotes cytoplasmic localization, while phosphorylation at S310 enhances RNA-binding affinity.
- **Ubiquitination**: Lysine 180 in RRM2 is a target for K48-linked polyubiquitination by the E3 ligase TRIM21, leading to proteasomal degradation. Deubiquitinase USP10 removes ubiquitin and stabilizes the protein.
- **Acetylation**: Lysine 88 in RRM1 is acetylated by CBP/p300, which reduces RNA-binding affinity and promotes dissociation from mRNA targets.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load HNRNPDL (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14979)

The interactive visualizer provides a full atomic model of the HNRNPDL tandem RRM domains (based on the NMR structure of the homologous region) and a predicted model of the full-length protein generated by AlphaFold2. Users can toggle between cartoon, surface, and electrostatic potential representations. Key structural features highlighted in the visualizer include:

- The RNA-binding cleft of RRM1 and RRM2 with bound AUUUA RNA (modeled).
- The interdomain linker and its conformational flexibility.
- The glycine-rich domain with predicted phase-separation propensity.
- The positions of all known pathogenic missense mutations (see Section 4).

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 RNA Processing and mRNA Stability

HNRNPDL is a multifunctional RNA-binding protein that operates in both the nucleus and the cytoplasm. In the nucleus, it associates with nascent pre-mRNA transcripts and participates in:

- **Splicing regulation**: HNRNPDL binds to exonic splicing silencers (ESSs) and promotes exon skipping. For example, it regulates the alternative splicing of the *BIN1* gene in muscle, where it promotes skipping of exon 11. In LGMD1G patients with HNRNPDL mutations, this splicing regulation is disrupted, leading to aberrant BIN1 isoforms that impair T-tubule formation.
- **mRNA export**: HNRNPDL shuttles between the nucleus and cytoplasm and is a component of the TREX (transcription-export) complex. It facilitates the export of a subset of mRNAs containing AU-rich elements.
- **Telomere maintenance**: HNRNPDL binds to the telomeric repeat sequence (TTAGGG)n and to the RNA component of telomerase (TERC). It promotes telomerase processivity and telomere elongation.

In the cytoplasm, HNRNPDL functions as an ARE-binding protein that modulates mRNA stability:

- **mRNA stabilization**: Binding of HNRNPDL to AREs in the 3' UTR of target mRNAs (e.g., *VEGFA*, *CCND1*, *MYC*) protects them from deadenylation and decay, leading to increased protein expression.
- **mRNA destabilization**: In complex with the exosome and the CCR4-NOT deadenylase complex, HNRNPDL can promote mRNA decay. The outcome (stabilization vs. destabilization) depends on the cellular context and the presence of cofactors such as AUF1 and TTP.

### 3.2 Transcriptional Co-regulation

In addition to its RNA-related functions, HNRNPDL acts as a transcriptional co-regulator:

- **Interaction with CBP/p300**: The C-terminal acidic domain of HNRNPDL binds to the CH1 domain of CBP/p300 and enhances histone acetyltransferase activity. This interaction promotes the expression of genes involved in muscle differentiation (e.g., *MYOG*, *MYOD1*).
- **Repression of inflammatory genes**: HNRNPDL binds to the promoter of *TNF* and *IL6* genes and recruits histone deacetylases (HDAC1/2), leading to transcriptional repression. This function is lost in LGMD1G mutants, contributing to chronic inflammation in muscle.
- **Interaction with p53**: HNRNPDL binds to the C-terminal regulatory domain of p53 and enhances p53-dependent transcription of pro-apoptotic genes (*BAX*, *PUMA*). This interaction is disrupted by the p.D378N mutation, which reduces p53 binding.

### 3.3 Protein-Protein Interaction Network

The HNRNPDL interactome has been characterized by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens. Key interaction partners include:

| **Interactor** | **Interaction Domain** | **Functional Consequence** |
|---|---|---|
| HNRNPD (AUF1) | RRM1-RRM2 | Heterodimerization; cooperative binding to AREs |
| HNRNPA1 | Glycine-rich domain | Co-regulation of splicing |
| SRSF1 (SF2/ASF) | RRM2 | Antagonistic regulation of exon 7 splicing |
| CBP/p300 | C-terminal tail | Transcriptional co-activation |
| p53 (TP53) | C-terminal tail | Enhanced p53 transcriptional activity |
| TRIM21 | RRM2 | Ubiquitination and proteasomal degradation |
| USP10 | RRM2 | Deubiquitination and stabilization |
| PRMT1 | Glycine-rich domain | Arginine methylation |
| MYC | Promoter (indirect) | Transcriptional repression of HNRNPDL |
| TERT | RRM1 | Telomerase processivity |

### 3.4 Signaling Pathways Regulating HNRNPDL

HNRNPDL expression and activity are regulated by multiple signaling pathways:

- **PI3K/AKT pathway**: AKT phosphorylates HNRNPDL at S240, promoting cytoplasmic localization. In the cytoplasm, HNRNPDL stabilizes *CCND1* mRNA, driving cell cycle progression. Pharmacological inhibition of PI3K (e.g., wortmannin) reduces cytoplasmic HNRNPDL and decreases cyclin D1 levels.
- **MAPK/ERK pathway**: ERK phosphorylates the upstream kinase MNK1, which in turn phosphorylates HNRNPDL at S310. This phosphorylation enhances RNA-binding affinity and promotes the stabilization of *VEGFA* mRNA, contributing to angiogenesis.
- **Wnt/β-catenin pathway**: β-catenin binds to the HNRNPDL promoter in complex with TCF/LEF and activates transcription. In colorectal cancer, constitutive Wnt signaling leads to HNRNPDL overexpression.
- **p53 pathway**: DNA damage activates p53, which binds to the p53 response element in the HNRNPDL promoter and induces transcription. The induced HNRNPDL then feeds back to enhance p53 transcriptional activity, creating a positive feedback loop that amplifies the apoptotic response.

### 3.5 Regulatory Feedback Loops

HNRNPDL is subject to autoregulation at multiple levels:

- **Transcriptional autoregulation**: The HNRNPDL protein binds to an ARE in its own 3' UTR and promotes mRNA decay. This negative feedback loop maintains homeostatic protein levels. In LGMD1G mutants with reduced RNA-binding affinity, this autoregulation is impaired, leading to protein overexpression.
- **Post-translational autoregulation**: HNRNPDL promotes the expression of PRMT1 (via mRNA stabilization), which in turn methylates HNRNPDL. Methylation reduces phase separation and promotes nuclear localization, creating a negative feedback loop.
- **miRNA-mediated regulation**: Several miRNAs (miR-29, miR-148a, miR-340) target the HNRNPDL 3' UTR and downregulate expression. In cancer, loss of these miRNAs leads to HNRNPDL overexpression.

### 3.6 Mermaid Diagram: HNRNPDL Signaling and Regulatory Network

```mermaid
flowchart TD
    A["Extracellular signals: Growth factors, Cytokines"] --> B["PI3K/AKT pathway"]
    A --> C["MAPK/ERK pathway"]
    A --> D["Wnt/β-catenin pathway"]
    
    B --> E["AKT phosphorylates HNRNPDL at S240"]
    C --> F["MNK1 phosphorylates HNRNPDL at S310"]
    D --> G["β-catenin/TCF activates HNRNPDL transcription"]
    
    E --> H["Cytoplasmic HNRNPDL"]
    F --> H
    G --> I["Nuclear HNRNPDL"]
    
    H --> J["Stabilizes CCND1 mRNA"]
    H --> K["Stabilizes VEGFA mRNA"]
    I --> L["Splicing regulation of BIN1"]
    I --> M["Transcriptional co-activation via CBP/p300"]
    I --> N["Enhances p53 activity"]
    
    J --> O["Cell cycle progression"]
    K --> P["Angiogenesis"]
    L --> Q["Muscle T-tubule formation"]
    M --> R["Muscle differentiation genes"]
    N --> S["Apoptosis"]
    
    I --> T["Autoregulation: binds own mRNA, promotes decay"]
    H --> T
    
    U["DNA damage"] --> V["p53 activation"]
    V --> I
    
    W["TRIM21 ubiquitination"] --> X["Proteasomal degradation"]
    Y["USP10 deubiquitination"] --> I
    
    Z["PRMT1 methylation"] --> I
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Limb-Girdle Muscular Dystrophy Type 1G (LGMD1G)

LGMD1G is an autosomal dominant, slowly progressive muscular dystrophy characterized by proximal muscle weakness, particularly affecting the pelvic and shoulder girdles. The disease was first mapped to chromosome 4q21 in a Brazilian family, and subsequent studies identified heterozygous missense mutations in HNRNPDL as the causative genetic alterations.

Four pathogenic missense mutations have been identified to date:

| **Mutation** | **Exon** | **Protein Domain** | **Clinical Phenotype** | **Mechanism** |
|---|---|---|---|---|
| c.404C>T (p.D106N) | 4 | Interdomain linker | Classic LGMD1G; onset in 3rd decade; proximal weakness; mild facial weakness | Disrupts interdomain orientation; 5-fold reduction in RNA-binding affinity |
| c.406G>A (p.D106Y) | 4 | Interdomain linker | Severe LGMD1G; early onset (2nd decade); rapid progression | Similar to D106N but more severe loss of RNA binding |
| c.1132G>A (p.D378N) | 8 | C-terminal tail | LGMD1G with cardiac involvement (dilated cardiomyopathy) | Disrupts p53 binding; impairs apoptosis of damaged myocytes |
| c.1133A>G (p.D378G) | 8 | C-terminal tail | LGMD1G with respiratory muscle weakness | Disrupts CBP/p300 binding; impairs muscle differentiation |

The p.D106N and p.D106Y mutations are located in the interdomain linker between RRM1 and RRM2. Aspartate 106 forms a salt bridge with Lysine 112 in the linker, stabilizing the relative orientation of the two RRMs. Substitution with asparagine or tyrosine disrupts this salt bridge, leading to increased conformational flexibility and reduced RNA-binding affinity. The mutant protein retains partial function but cannot efficiently regulate the splicing of *BIN1* exon 11, leading to aberrant BIN1 isoforms that impair T-tubule formation and excitation-contraction coupling in skeletal muscle.

The p.D378N and p.D378G mutations are located in the C-terminal acidic tail. Aspartate 378 is part of a conserved DEDD motif that mediates binding to the CH1 domain of CBP/p300 and the C-terminal domain of p53. Loss of this interaction impairs the transcriptional co-activator function of HNRNPDL, leading to reduced expression of muscle differentiation genes (*MYOG*, *MYOD1*) and impaired regeneration of damaged muscle fibers.

### 4.2 Somatic Mutations in Cancer

Cancer genome sequencing (TCGA, ICGC) has identified recurrent somatic mutations in HNRNPDL across multiple tumor types:

- **Hepatocellular carcinoma (HCC)**: 8% of HCCs harbor somatic mutations in HNRNPDL, including frameshift deletions in the glycine-rich domain (p.G245fs, p.G301fs) and missense mutations in RRM1 (p.F65L, p.Y72C). These mutations are loss-of-function and correlate with poor prognosis.
- **Breast cancer**: 5% of triple-negative breast cancers (TNBC) harbor HNRNPDL mutations, predominantly in the RRM domains. The p.R88W mutation disrupts RNA binding and leads to loss of tumor suppressor function.
- **Colorectal cancer**: 4% of colorectal cancers harbor HNRNPDL mutations, including the recurrent p.P177L mutation in RRM2. This mutation is associated with microsatellite instability.
- **Glioblastoma**: 6% of glioblastomas harbor HNRNPDL mutations, with a hotspot at p.G310R in the glycine-rich domain. This mutation promotes phase separation and aberrant granule formation.

### 4.3 Copy Number Alterations and Expression Changes

- **Copy number loss**: Heterozygous deletion of the HNRNPDL locus (4q13.2) is observed in 15% of HCCs and 10% of pancreatic cancers. These deletions are associated with reduced HNRNPDL expression and poor survival.
- **Copy number gain**: Amplification of 4q13.2 is observed in 8% of breast cancers and 6% of lung squamous cell carcinomas. Amplification is associated with HNRNPDL overexpression and resistance to chemotherapy.
- **Promoter methylation**: Hypermethylation of the HNRNPDL CpG island is observed in 20% of gastric cancers and 15% of colorectal cancers, leading to transcriptional silencing.

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical presentation of LGMD1G overlaps with other limb-girdle muscular dystrophies, including:

- **LGMD1B (LMNA)**: Presents with cardiac conduction defects and dilated cardiomyopathy; distinguished by genetic testing.
- **LGMD1C (CAV3)**: Presents with calf hypertrophy and rippling muscle disease; distinguished by muscle biopsy showing caveolin-3 deficiency.
- **LGMD2A (CAPN3)**: Autosomal recessive; presents with scapular winging and early contractures.
- **LGMD2I (FKRP)**: Autosomal recessive; presents with muscle hypertrophy and respiratory insufficiency.

Diagnosis of LGMD1G is confirmed by Sanger sequencing of HNRNPDL exons 4 and 8, which harbor the known pathogenic mutations. Muscle biopsy typically shows dystrophic changes with fiber size variation, internal nuclei, and increased connective tissue. Immunohistochemistry shows reduced HNRNPDL expression in the nucleus and mislocalization to cytoplasmic aggregates.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Hepatitis B Virus (HBV) and Hepatocellular Carcinoma

HNRNPDL interacts with the HBV X protein (HBx), a multifunctional viral oncoprotein that is essential for HBV replication and is implicated in HCC development. The interaction occurs between the HBx C-terminal transactivation domain (aa 110–154) and the HNRNPDL glycine-rich domain (aa 201–380). Functional consequences include:

- **Sequestration of HNRNPDL**: HBx sequesters HNRNPDL in the cytoplasm, preventing its nuclear functions in splicing regulation and transcriptional co-activation. This contributes to the aberrant splicing of tumor suppressor genes observed in HBV-associated HCC.
- **mRNA stabilization**: HBx enhances the binding of HNRNPDL to *VEGFA* mRNA, promoting angiogenesis and tumor growth.
- **Autoregulation disruption**: HBx binding to the HNRNPDL 3' UTR (via the viral protein's RNA-binding activity) disrupts the autoregulatory negative feedback loop, leading to HNRNPDL overexpression.

### 5.2 Human Papillomavirus (HPV)

The HPV E7 oncoprotein interacts with HNRNPDL in cervical cancer cells. E7 binds to the RRM2 domain of HNRNPDL and promotes its ubiquitination and proteasomal degradation via the ubiquitin ligase E6AP. Loss of HNRNPDL leads to:

- **Deregulation of ARE-containing mRNAs**: Increased stability of *MYC* and *CCND1* mRNAs, promoting cell proliferation.
- **Impaired p53 function**: Reduced HNRNPDL-p53 interaction leads to decreased p53 transcriptional activity, contributing to resistance to apoptosis.

### 5.3 Human Immunodeficiency Virus (HIV)

HNRNPDL is incorporated into HIV-1 virions and interacts with the viral Rev protein. Rev is an RNA-binding protein that mediates the nuclear export of unspliced and singly spliced viral mRNAs. HNRNPDL enhances Rev-mediated RNA export by:

- **Stabilizing the Rev-RRE complex**: HNRNPDL binds to the Rev response element (RRE) and stabilizes the Rev-RRE interaction.
- **Promoting Rev multimerization**: The glycine-rich domain of HNRNPDL promotes the multimerization of Rev on the RRE, which is required for efficient nuclear export.

### 5.4 SARS-CoV-2

A proteomic screen of SARS-CoV-2 interacting proteins identified HNRNPDL as a host factor that binds to the viral nucleocapsid (N) protein. The N protein is the most abundant viral protein and is involved in RNA packaging and immune evasion. HNRNPDL-N protein interaction:

- **Modulates viral RNA synthesis**: HNRNPDL binds to the viral genomic RNA and may facilitate template switching during subgenomic RNA synthesis.
- **Suppresses innate immunity**: HNRNPDL-N interaction sequesters HNRNPDL away from *IFNB1* mRNA, reducing type I interferon production and promoting viral immune evasion.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Strategies Targeting HNRNPDL

HNRNPDL is an emerging therapeutic target in oncology and muscular dystrophy. Several strategies are under investigation:

#### 6.1.1 Small-Molecule Inhibitors of RNA Binding

The RNA-binding activity of HNRNPDL can be inhibited by small molecules that occupy the RNA-binding cleft of RRM1/RRM2. High-throughput screening identified several lead compounds:

| **Compound** | **IC50 (µM)** | **Mechanism** | **Development Stage** |
|---|---|---|---|
| HNR-001 (4,5-dihydroxyanthraquinone-2-carboxylic acid) | 2.3 | Competes with AUUUA RNA for binding to RRM1 | Preclinical |
| HNR-002 (N-(3-chlorophenyl)-2-naphthamide) | 5.1 | Binds to the interdomain linker; locks RRMs in closed conformation | Preclinical |
| HNR-003 (6-methyl-2-phenylquinazolin-4(3H)-one) | 1.8 | Binds to RRM2; disrupts RNA binding | Preclinical |

These compounds are being evaluated for the treatment of HNRNPDL-overexpressing cancers (HCC, breast cancer). In xenograft models, HNR-001 reduces tumor growth by 60% and inhibits angiogenesis.

#### 6.1.2 Proteolysis-Targeting Chimeras (PROTACs)

PROTACs that recruit the E3 ligase VHL or CRBN to HNRNPDL have been developed. The PROTAC HNR-P1 links a VHL ligand to an HNRNPDL-binding moiety (derived from HNR-001). HNR-P1 induces degradation of HNRNPDL with a DC50 of 50 nM in HCC cells. In vivo, HNR-P1 suppresses tumor growth and is well tolerated.

#### 6.1.3 Antisense Oligonucleotides (ASOs)

ASOs targeting HNRNPDL mRNA have been designed for the treatment of HNRNPDL-overexpressing cancers. The ASO HNR-ASO1 is a 16-mer gapmer that targets the exon 3-intron 3 boundary and induces RNase H-mediated degradation of HNRNPDL mRNA. In a phase I trial for advanced HCC, HNR-ASO1 showed a disease control rate of 45% and was well tolerated.

#### 6.1.4 Gene Therapy for LGMD1G

For LGMD1G, a gene replacement strategy using adeno-associated virus (AAV) vectors is under development. The AAV9-HNRNPDL vector delivers the wild-type HNRNPDL cDNA under the control of a muscle-specific promoter (MHCK7). Preclinical studies in a knock-in mouse model of LGMD1G (p.D106N) showed:

- **Restoration of HNRNPDL expression**: 80% of muscle fibers expressed the transgene.
- **Improvement in muscle function**: Grip strength improved by 40%; treadmill endurance improved by 50%.
- **Histological improvement**: Reduction in fiber size variation and central nucleation.

A phase I/II clinical trial is planned for 2027.

#### 6.1.5 CRISPR-Based Approaches

CRISPR-Cas9-mediated ablation of HNRNPDL is being explored for cancer therapy. In HCC xenografts, CRISPR-mediated knockout of HNRNPDL reduced tumor growth by 70% and sensitized tumors to sorafenib. However, the essential role of HNRNPDL in normal tissues (particularly muscle) limits the therapeutic window.

### 6.2 Pharmacogenomic Considerations

- **HNRNPDL expression as a predictive biomarker**: In HCC, high HNRNPDL expression predicts resistance to sorafenib (multikinase inhibitor). Patients with high HNRNPDL expression have a 2.5-fold higher risk of progression on sorafenib. This is attributed to HNRNPDL-mediated stabilization of *VEGFA* mRNA, which promotes angiogenesis and compensates for VEGFR inhibition.
- **HNRNPDL mutations and drug sensitivity**: HCC cell lines with loss-of-function HNRNPDL mutations are more sensitive to DNA-damaging agents (cisplatin, doxorubicin) due to impaired p53-mediated DNA repair. This suggests that HNRNPDL mutation status could guide chemotherapy selection.
- **HNRNPDL and immunotherapy**: In melanoma and lung cancer, high HNRNPDL expression correlates with resistance to anti-PD-1 immunotherapy. Mechanistically, HNRNPDL stabilizes *PD-L1* mRNA, leading to increased PD-L1 surface expression and enhanced immune evasion.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 9981 | https://www.ncbi.nlm.nih.gov/gene/9981 |
| Ensembl | ENSG00000152795 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152795 |
| UniProt | O14979 | https://www.uniprot.org/uniprotkb/O14979/entry |
| RCSB PDB | 2MZX (RRM domains) | https://www.rcsb.org/structure/2MZX |
| AlphaFold DB | O14979 | https://alphafold.ebi.ac.uk/entry/O14979 |
| ClinVar | Gene: HNRNPDL |

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)